federal judge dismissed a lawsuit filed by two former corporate private eyes who accused GlaxoSmithKline (GSK) of hiring them under false pretenses to investigate a whistleblower in China, a move that led to their imprisonment amid a bribery scandal that subsequently engulfed the drug maker.

Peter Humphrey and Yu Yingzeng had alleged Glaxo lied about its reasons for hiring the couple in 2013. At that time, Glaxo executives in China asked them to investigate a former employee, who was suspected of becoming a whistleblower and disclosing the bribery scheme. Someone had already sent details to the Chinese government and Glaxo management in the U.K.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy